Methods and compositions for the treatment of pain, inflammation and cancer
申请人:Barbosa Joseph
公开号:US20080194557A1
公开(公告)日:2008-08-14
This invention relates to methods of treating, managing and preventing pain, inflammation, cancer, and ocular diseases and disorders, and to compounds and pharmaceutical compositions useful in such methods.
Methods and compositions for the treatment of body composition disorders
申请人:Barbosa Joseph
公开号:US20080200458A1
公开(公告)日:2008-08-21
This invention relates to methods of treating, managing and preventing body composition disorders, and to compounds and pharmaceutical compositions useful in such methods.
本发明涉及治疗、管理和预防身体组成失调的方法,以及在这些方法中有用的化合物和制药组合物。
Bi-functional complexes and methods for making and using such complexes
申请人:Gouliaev Alex Haahr
公开号:US11225655B2
公开(公告)日:2022-01-18
The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.
Homo-cysteinyl peptide inhibitors of the L1 metallo-β-lactamase, and SAR as determined by combinatorial library synthesis
作者:Qin Sun、Andy Law、Michael W. Crowder、H. Mario Geysen
DOI:10.1016/j.bmcl.2006.07.001
日期:2006.10
Homo-cysteinyl peptides were found to be more active than cysteinyl peptides toward L1 metallo-beta-lactamase as reversible competitive inhibitors. A combinatorial library of more than 90 homo-cysteinyl peptides was synthesized and screened for their inhibitory activity toward the L1 enzyme. A systematic structure-activity relationship analysis has revealed the preferred interaction groups for Ll conserved binding sites of beta-lactam substrates. The most active compound 95b, had a K-i of 2.1 nM. (c) 2006 Published by Elsevier Ltd.